Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses.
EMBO Mol Med
; 15(5): e17580, 2023 05 08.
Article
em En
| MEDLINE
| ID: mdl-36946379
ABSTRACT
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the risk of progression to severe COVID-19. However, the impact of nirmatrelvir treatment on the development of SARS-CoV-2-specific adaptive immune responses is unknown. Here, by using mouse models of SARS-CoV-2 infection, we show that nirmatrelvir administration blunts the development of SARS-CoV-2-specific antibody and T cell responses. Accordingly, upon secondary challenge, nirmatrelvir-treated mice recruited significantly fewer memory T and B cells to the infected lungs and mediastinal lymph nodes, respectively. Together, the data highlight a potential negative impact of nirmatrelvir treatment with important implications for clinical management and might help explain the virological and/or symptomatic relapse after treatment completion reported in some individuals.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Imunidade Adaptativa
/
Tratamento Farmacológico da COVID-19
/
Lactamas
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article